HARVARD BIOSCIENCE INC (HBIO): Nasdaq/NYSE listing notice — Harvard Bioscience gets 180-day Nasdaq bid-price extension, transfers to Capital Market

HARVARD BIOSCIENCE INC

Nasdaq granted until March 30, 2026 to reach $1.00 minimum bid price for 10 consecutive days.
Common stock transferred from Nasdaq Global Market to Capital Market effective October 3, 2025; ticker HBIO remains.
Company previously disclosed deficiency in April 2025 when bid price fell below $1.00 for 30 consecutive days.
If compliance not met by March 30, 2026, delisting proceedings may begin; Company may consider a reverse stock split.
No assurance of regaining compliance; Company will monitor closing bid price and evaluate options.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

HARVARD BIOSCIENCE INC received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

October 2, 2025, Harvard Bioscience, Inc., (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it had been granted an additional 180 days, or until March 30, 2026 (the “Second Compliance Period”), to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”), based on the Company meeting

View on SEC.gov

Browse all listing & compliance notices →

HARVARD BIOSCIENCE INC filing history →

Source: SEC EDGAR

accession 0001171843-25-006260

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.